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Abstract 
 
This study was to evaluate the potential benefits of two products (Oxyzyme® & 
Iodozyme®) into a leg ulcer service in South Staffordshire, UK.   
 
A randomised controlled Trial (RCT) was used to evaluate time to ulcer healing, 
quality of life, pain and cost effectiveness.   
 
100 patients were randomised to receive either Oxyzyme/ Iodozyme (active group) 
or standard care (control group) with venous or mixed arterio-venous ulcers.  
Patients were evaluated weekly up to 12 weeks, with further follow up at 24 weeks. 
Whilst there was a small benefit in terms of healing over follow up using the Cox 
Proportional Hazards Model, this did not achieve a standard level of statistical 
significance (Hazard Ratio= 1.13, 95%CI 0.64 to 2.02, p=0.67) after adjustment for 
confounding factors.  Patients with high protease activity showed an improved and 
faster healing in the active group, (HR=1.35, 95%CI 0.63, 2.87)p=0.44. 
 
 
The active group required significantly fewer dressing changes (14.8 versus 10.0, 
p=0.033). Despite the dressing costs being higher, there was a significantly lower 
cost of nursing time, leading to a greater cost effectiveness in terms of cost per 
healed ulcer (£977 versus £1071. A Markov model used to assess cost 
effectiveness in the main trial found that the control group had slightly better 
outcomes (12 more ulcer free weeks), but at a substantially greater cost (£5,031). 
When those with high protease activity the cost in the active group dominated, with 
lower cost (-£2,450) and an improved outcome (29 more ulcer free weeks).  
 
Health related quality of life (HRQoL) and pain significantly improved over the 
assessment period, though there was no difference between the treatment groups. 
 
The use of Oxyzyme® & Iodozyme®) could provide better value for money in the 
management of venous and mixed arterio-venous ulcers than standard care in a 
community leg ulcer service. 
 Submitted version 1.0, 28th July 2014 
 
 
 4 
Introduction 
 
 
Leg ulceration remains a major health care problem affecting over 100,000 people 
at any one time in the UK [1]. Despite advances in the delivery of care and 
improvements in assessment and treatment with compression many patients 
experience protracted periods of time unhealed causing significant impact on their 
quality of life. In addition to the personal cost this is a large drain on health care 
resources at a time of pressure on resources in the NHS [2]. 
 
Traditional approaches to treatment of venous and mixed ulceration have focused 
on the application of compression as the most important component of treatment 
[3,4]. Relatively little attention has been placed on understanding how manipulation 
of the wound environment may enhance healing, particularly when wounds have 
become chronic. New products are emerging that could transform this situation and 
promote healing by controlling and optimising the micro-environment of the wound 
cavity. However these products must be evaluated to demonstrate their potential 
benefit in terms of clinical and cost effectiveness [5].  
 
An adequate supply of oxygen has long been recognised as key to successful 
wound healing. Until recently approaches to avoiding a restrictive hypoxia in wounds 
have relied on systemic approaches such as hyperbaric oxygen or inhaled oxygen 
[6,7]  The new dressings evaluated in this study represent a clinical development in 
this area through the development of new, active hydrogel dressings that 
incorporate an enzyme system intended to optimise the conditions within the wound 
bed.  Whilst the system undertakes a programmed production of iodine, the pH is 
optimised by the generation of gluconate and the oxygen balance is restored as a 
consequence of another by-product in the form of dissolved oxygen at the interface 
between the wound and dressing.  The overall effects of the micro-environmental 
optimisation (including moisture control) become apparent at the visual clinical level 
(through continued use) as enhanced autolytic debridement, healthy granulation and 
orderly epithelisation.  
 
 
A variety of enzymes are deployed by the cells present in and around the wound 
with which to break down the matrix in a controlled manner, as an essential part of 
the tissue re-modelling that is the basis of active healing.  Matrix 
Metalloproteinases are prominent components of this set, and they fulfil a central 
role in the processes of healing, as well as in normal tissue homeostasis. As part 
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 5 
and parcel of these regenerative and maintenance procedures, blood vessels that 
deliver oxygen and nutrients to the new tissue must undergo radical modification.  
Building of new blood vessels (angiogenesis) is particularly dependent on the 
activity of MMPs to clear away damaged extra cellular matrix in order to make 
space for the new microvascular structures required to sustain the new tissues. 
 
The role of MMPs in wound healing is so complex that diagnostic opportunities 
based on measurements of MMP concentration or activity are only just becoming 
possible.  In humans there are at least 24 different MMPs with varying roles and 
produced in a variety of cell types.  This family of enzymes is involved in complex 
multiple molecular interactions and biochemical pathways with other proteinases 
and substrates. 
 
The Oxyzyme® dressing (Archimed, Knutsford UK) being evaluated in this study has 
been developed to provide a new level of support to the process of wound healing.  
At the same time as impeding microbial growth, it optimises the environment of the 
wound bed for favourable biochemical and cellular processes.  The dressing 
contains glucose oxidase to make hydrogen peroxide and a halide, iodide, to make 
hypoiodite (similar to hypochlorite) which leads to iodine. When the dressing is 
removed from its airtight package and the two layers are brought into contact with 
each other, the oxidase enzyme within the top layer is ready to start its reaction with 
oxygen.   Just as leukocytes activate their oxidase enzyme to generate hydrogen 
peroxide, so the assembled 2-layer dressing uses oxygen from the air to produce a 
steady flow of hydrogen peroxide in the dressing. While the dressing is in contact 
with the wound surface, the hydrogen peroxide is converted to water and dissolved 
oxygen by serum catalase in the wound.  The wound bed becomes rich in locally 
available oxygen, with all of its associated benefits, to work in harmony with the 
antimicrobial effects of the iodine and the various other optimising effects of the 
dressing.  
 
 
Iodozyme® (Archimed, Knusford, UK) is a sister product to Oxyzme® and has been 
developed for patients who are considered to have particular problems with chronic 
infection or bacterial burden. It is based on the same dressing characteristics and 
differs only in the amount of iodine produced and the absorptive capacity of the 
wound contact gel. The assembled dressing ready for use comprises a two layer, 
composite hydrogel.   As with Oxyzyme, it absorbs wound fluid while the gel 
conforms to the wound bed, maintaining an optimised moist environment. The level 
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of iodine produced in the dressing is substantially higher than produced by the 
Oxyzyme product. However, both dressings have lower levels of Iodine compared 
with other Iodine based dressings, but have similar antimicrobial properties. 
 
The aim of this trial was to examine the relative clinical and cost effectiveness of 
using these complex dressings in the healing of venous and mixed venous and 
arterial ulceration within a well- established wound care service. 
 
The aim of the sub-protocol in this trial was to determine whether the use of the 
Oxyzyme® and Iodozyme® dressings modulate the levels of metalloproteinases, 
and from this to determine whether such a modification is influencing healing in 
patients with high initial levels of these enzymes. Details of this study will be 
published elsewhere. 
 
 
Patients and Methods 
 
The study was a prospective, randomised, parallel groups, open study to compare 
the use of a new dressing regimen Oxyzyme/Iodozyme (active group) with standard 
treatment (control group) for leg ulceration in the healing of venous and mixed 
venous/ arterial ulceration. 
  
Primary objective: 
 
 The main objective was to determine the relative effectiveness of 
introducing the trial products compared with standard care.  Effectiveness was 
defined as complete ulcer closure on the reference ulcerated limb (100% re-
epithelialization) at 12 weeks or before if this occurred. 
 
Secondary objectives: 
  
 To determine which was the most cost effective treatment in ulcer healing. 
 To determine which wounds benefitted most from the intervention 
 To determine whether pain improved with treatment. 
 To determine which treatment gave the best patient outcome in terms of  
health related quality of life (HRQoL) 
 To examine adverse events associated with treatment.  
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 7 
 To determine longer treatment follow up in patients with harder to heal 
ulcers (to 24 weeks). 
 
 
This study was designed as a preliminary study to evaluate the potential benefit of 
these advanced wound therapies in healing patients with chronic leg ulceration. A 
sample size of 100 was selected, though this was not based on a formal power 
calculation as no previous studies had been undertaken to allow for this calculation. 
It was anticipated that a sample of 100 patients would provide insight into the future 
potential of the treatment and allow for more precise power calculations in further 
studies.   
 
Patients were drawn from the South Staffordshire PCT Tissue Viability Service.  All 
patients within the service who met the inclusion criteria were considered for this 
trial. Patients who newly presented for treatment within the clinical areas of the Trust 
were also considered for entry during the study period.   
 
The following criteria had to be met before a patient was recruited to the trial. 
 
Inclusion Criteria  
 
Age:   At least 18 years of age. 
 
Gender:   Males 
   Females - provided they were not pregnant or breastfeeding 
 
Presentation:  Patients with a venous ulcer (ABPI defined as >0.8) 
   or 
  Patients with a mixed ulcer (venous ulcer with mild concurrent  
  peripheral arterial disease (ABPI greater than 0.6)  
 
Diagnosis:    Patients with ankle brachial pressure index (ABPI) >0.8 were  
   considered to have minimal arterial disease using a standard  
   procedure.  
  
A diagnosis of venous disease was established through clinical criteria for chronic 
venous insufficiency. This included the presence of varicose veins, evidence of 
liopodermatosclerosis, varicose eczema and ulceration in the ankle and lower calf 
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area. Previous history of deep vein thrombosis and varicose vein treatment were 
also used as part of the criteria. 
 
Patients with mixed venous disease with mild peripheral arterial disease were 
classified according to the level of the ankle to brachial pressure index. An ABPI > 
0.8 was considered safe for high compression (40 mmHg at the ankle) with minimal 
peripheral arterial occlusive disease present. An ulcerated limb with an ABPI of 
between 0.6 and 0.8 was considered to have a mixed arterial-venous aetiology and 
was treated with a lower level of compression (<25mmHg).   
 
Wound characteristics included mild or moderate levels of exudate, with an ulcer 
size between 2 and 50 cm2.  The wound had to present for less than one year, with 
healthy peri-wound skin.  Only patients who were willing and able to give written 
informed consent were eligible for inclusion in the trial.   
 
 
 
Exclusion Criteria 
 
Specific exclusions included severe peripheral arterial occlusive disease defined as 
an ABPI of < 0.6 in whom it is unsafe to receive compression.  Patients had to be 
able to tolerate the correct level of compression for their clinical   condition.  Patients 
who experienced an acute deep vein thrombosis within the last 3 months, or who 
had undergone surgery for chronic venous insufficiency in the last 2 months were 
also excluded, as were patients who had undergone arterial reconstruction or 
angioplasty for peripheral arterial occlusive disease in the last 3 months.  
 
Patients with a clinically defined active cellulitis which was being treated using 
systemic antibiotics at the start of the trial were excluded.  However, should cellulitis 
develop during the trial they did not need to be withdrawn.  This was however, noted 
as an adverse events. 
 
Patients receiving treatment for thyroid disorders including treatment with thyroxine 
and Iodine and those on lithium carbonate were also excluded.  Patients with a 
known hypersensitivity to one of the components of the new dressings and those 
with peri-wound maceration or uncontrolled varicose eczema around the ulceration 
were not included. Finally, patients confined to bed and pregnant or breastfeeding 
were excluded from the trial. 
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Patient Recruitment  
 
The clinical investigator identified eligible patients according to the selection criteria 
and an agreed checklist.  Patients were questioned on their previous medical history 
and their limb and ulcer were examined.  All patients who did not fit the entry 
requirements for the trial were excluded. Before being admitted to the clinical study, 
the patient consented to participate, after the nature, scope and possible 
consequences of the study had been explained in an understandable form.  The 
patient’s GP was informed of their participation. 
 
 
Randomisation 
 
The Clinical Nurse Specialist held the randomisation envelopes. Randomisation 
took place following the eligibility check and after obtaining the patient's written 
informed consent.  To assure equality of groups the randomisation was stratified 
according to whether the patient had pure venous or mixed aetiology ulceration. 
Randomisation was performed by opening an envelope containing the patient's trial 
number and details of the treatment to be applied after eligibility criteria had been 
met and written consent had been given.  
 
Patients with bilateral leg ulceration were randomised to one dressing system that 
was used on both limbs. The study limb was taken as the limb which had the largest 
area of ulceration on wound measurement.    
 
In total there were two patient groups 
 
Group I (Active): patients receiving Oxyzyme/ Iodozyme (in conjunction with 
compression therapy based on formulary recommendations for the Service),  
 
Group II (Control): patients receiving standard care (continuation with current 
treatment regimen including compression therapy based on formulary 
recommendations for the Service). 
 
 
Clinical Measures:  
 
The main clinical outcome was complete ulcer closure on the reference limb 
(100% re-epithelialization) at 12 weeks or before if this occurred. 
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At the initial assessment the patient’s ulcer was drawn using acetate and pen and 
the wound area was estimated by planimetry. The wound area was re-measured at 
each weekly assessment visit although the wound might have been redressed more 
frequently between these visits. 
 
Non invasive investigation using Doppler Ultrasound was used to confirm the arterial 
status of the patient’s leg using Ankle Brachial Pressure Index (ABPI) measurement.  
Other assessments made during their initial assessment included: 
 History of ulceration 
 Relevant medical history 
 Pain assessment using the VAS from the McGill Pain questionnaire 
 Health related quality of life – This was repeated at 12 weeks or earlier if the 
 wound healed before this time. A final assessment of quality of life was 
 made at 24 weeks on all patients, both healed and unhealed. 
 
  
Treatment interventions. 
 
For all included patients the scheduled treatment duration was 12 weeks. Patients 
were allocated through a process of randomisation to either active or control 
treatment based on the local wound care formulary.  
 
The dressings were applied according to manufacturer’s instructions and local 
agreed policy. The investigator was responsible for ensuring that all clinical staff 
were familiar with the new dressings being studied and that the application and 
removal methods were adhered to. In addition, all other treatments used conformed 
to the agreed local wound formulary that supports decision making in this service.  
Wound swabs were taken at each weekly dressing change to examine the levls of 
MMP activity using a standardised proprietary test (Reverse ELTABA, Mologic 
Limited, Bedford, UK). 
 
Because of the variability of the different wounds some patients required more 
frequent dressing renewal according to clinical need. Typical reasons for increasing 
the frequency of dressing change included heavy exudate or wounds with a large 
surface area. Extra dressing changes by health professionals were recorded in the 
case report form (CRF) as appropriate. Patients who suffered from bilateral 
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ulceration received the trial products on both limbs provided that the wounds on the 
other limb were suitable to receive the dressings.  
 
 
Use of secondary dressings 
 
Oxyzyme® and Iodozyme® were applied to the wound bed as primary dressings 
and required a secondary dressing to secure them in place. In order to allow the 
dressings to generate oxygen and iodine, a breathable secondary dressing was 
selected. The level of exudate from the wound guided the selection of secondary 
dressing based on the criteria below. All of these dressings were included within 
the wound care formulary. 
 
Exudate level Dressing 
choice 
Rationale 
Low exudate level Film dressing Retain the moisture within the 
primary dressing and avoid from 
drying out 
Low / medium level Surgipad/thin 
foam 
Allow moisture evaporation 
through the vapour permeable 
outer layer of the secondary 
dressing 
 
 
Application of compression 
 
Patients with venous ulceration were treated with high compression therapy using 
the wound care formulary recommendations which follow national guidelines and 
best available evidence. Systems of high compression used were multi-layer which 
are designed to apply a resting pressure of approximately 40mmHg.  
 
Patients with a level of concurrent peripheral arterial disease were treated with 
reduced compression bandage systems that aimed to apply a pressure not greater 
than 25mmHg.  
 
Patients whose ulcer healed during the study were fitted with appropriate 
compression hosiery to help reduce the risk of ulcer recurrence.  
 
Patients were seen every 1 week  3 days until the 12th week for wound 
assessment, with all the visits being documented in the case report form (CRF). 
Patients were not assessed between the 12th assessment visit and week 24.  A 
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final evaluation of the ulcer status was undertaken at week 24 with the health 
related quality of life assessment.  
 
At each visit the investigator performed a clinical assessment of the wound 
according to a standard protocol, and assessed the size of the wound. 
Between the weekly scheduled visits, every dressing and compression system 
change was documented by the investigator in an appropriate form. At each 
dressing change, the primary and secondary wound dressing was changed as 
well as the compression. 
The treatment was stopped, temporarily or permanently, before the required 
12 weeks had been completed if the investigator deemed this to be necessary. 
This was then documented in the case report form.  A temporary discontinuation 
of the allocated treatment system did not exceed 2 weeks.  After this time, it was 
assumed to be a permanent discontinuation. 
 
Patient’s Quality of Life 
Quality of life was assessed using a validated tool (VLU-QOL) [8].  This gives 
scores in three domains, namely activities; psychological and symptom distress.  
Each score is transformed to give a score from zero (perfect health) to 100 (worst 
possible health).  Thus, any reduction in VLU-QOL score is indicative of an 
improvement in health related quality of life.  The visual analogue (VA) scale for 
perceived pain was taken from the McGill short form pain scale (9). 
The patient’s quality of life was assessed at baseline and at the end of the 
treatment period (Week 12 or at the end of the tested dressing treatment, 
whatever the reason) and at 24 weeks in accordance with a standard protocol. 
 
The investigator was responsible for identifying adverse events that occurred to 
each participant throughout the study. An adverse event could occur at any time 
during the conduct of the study, in any phase of the study or after the study was 
completed. An adverse event could have been identified by the investigator or 
reported by the participant. 
 
Cost Effectiveness Analysis 
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The cost information was collected at each weekly visit for both groups.  This 
included information on bandages and dressings used together with the number of 
applications within that week.  Information on bandage and dressing usage during 
the interim visits was collected to confirm that the management of patients did not 
differ between the weekly visits and interim visits.  Information on the unit cost of 
dressings and bandages was based on the British National Formulary [10] which 
was accessed during the analysis phase of the study from September 2012 to 
November 2012.  Nurse time was estimated at 27 minutes contact time based on 
previous studies and information collected on treatment changes during the present 
study.  The cost of a visit was estimated as £27 per visit based on PSSRU 2011 
data [11].  Hosiery costs were assumed to be zero as these were not renewed at 
dressing changes, but rewashed.  Hosiery was also used to maintain the healed 
ulcer.   
 
Cost effectiveness was determined in two ways.  Firstly the total cost of care was 
determined in the two groups during the active treatment phase of the trial up to 
complete healing, withdrawal or reaching 12 weeks of treatment.  A cost per 
healed ulcer was then calculated based on this information.   
 
Secondly a Markov chain analysis was used to examine the costs and healing 
over time to determine whether this led to a more cost effective approach.  The 
Markov method is well established in health economic analysis.  It is based on the 
patients being in a variety of health states at weekly intervals during their 
treatment.  For the purposes of this study the health states were given as:  
1. On randomised treatment: patients receiving the randomised treatment. 
2. Withdrawal from treatment.  In patients who withdrew this health state was 
assumed to be for a two week period. 
3. Off study treatment.  This was assumed to occur after the two weeks 
withdrawal period where patients were still being treated up to 12 week cut-
off. 
4. Healed. Patients were assumed not to require leg ulcer treatment and as 
such no cost was associated with this health state. 
Information on how long each patient was in each health state were collated and 
costs for each health state were determined from the trial data.  Effectiveness was 
estimated by determining the number of ulcer free weeks for the two randomised 
groups and estimating the Incremental cost effectiveness ratio (ICER) as follows: 
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ICER=  Cost of treatment (Control) - Cost treatment (Active)  
Ulcer free weeks (Control) – Ulcer free weeks (Active) 
   
Trial Monitoring 
 
The Trial Monitor telephoned and visited the centre at appropriate intervals to check 
on the progress of the evaluation, compliance with the protocol and to ensure the 
acceptability of the data. The on-site checking of the case record forms for 
completeness and clarity, spot-checks and cross-checks with source documents 
(giving due consideration to data protection and medical confidentiality) were carried 
out by the trial monitor. 
 
 
Before the start of the study the protocol was submitted to Leeds West Research 
Ethics Committee (REC) for approval. In addition the research was registered with 
the R&D office of the trust. 
 
 
Analysis  
 
Data were entered on to an ACCESS database designed for the trial. All analysis 
was undertaken using the Stata 11.0 statistical package. 
 
All patients with at least one follow up visit were included in the analysis according to 
the randomised treatment. Principal analysis was on an “intention to treat” basis, 
namely according to what the patient was randomised to, irrespective of their actual 
treatment. 
 
 
Baseline Data 
 
The baseline data were summarised using descriptive statistics by treatment group 
and overall.  Where baseline data were collected on each limb, this was 
summarised by trial limb. 
 
The principal endpoint was complete ulcer closure (100% epithelialisation) following 
twelve weeks of treatment.  This was undertaken using Kaplan Meier plots, with 
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statistical analysis using the Cox Proportional Hazards model which was used to 
determine the influence of confounding factors on this outcome. 
 
The quality of life data were analysed using a repeated measures mixed model 
using the REML method.  
 
Cost effectiveness analysis used a Markov model to determine the outcomes of 
treatment (ulcer free period) in relation to the cost of care and from this to estimate 
the cost effectiveness ratio. 
 
 
  
Results 
 
In total 100 patients were entered into the trial and randomised between February 
2011 and January 2012.  Figure 1 gives the trial flow diagram. Table 1 gives 
details of the patients in terms of their basic demography and selected allied 
health problems. 
 
Baseline Information 
 
In total 53 patients were randomised to a control dressing and 47 were 
randomised to the active group).  The average age of the participants was 69.5 
years, with similar distribution of ages between the two randomised groups.  
There was a roughly even split between men and women, with slightly fewer men 
in the active group. The groups were reasonably well matched for the selected 
health problems, with slightly more patients with hypertension and rheumatoid 
arthritis in the control group. 
 
Table 2 gives details of the venous and cardiovascular signs in the two arms of 
the trial.  Patients in the active group had slightly more signs of venous disease 
(varicose veins and venous surgery), though slightly fewer with history of 
myocardial infarction and arterial leg surgery.   No patients had a history of 
diabetic foot ulceration.   
 
Leg ulcer details are given in table 3.  Again, the randomised groups were 
reasonably matched.  Ulcer duration was on average 18 months, though this 
varied from one week to 30 years. There were a similar proportion of patients with 
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venous and mixed arterio-venous disease as the cause of ulceration, with similar 
proportions in each randomised group. Approximately one quarter had no exudate 
from their wounds, whilst one quarter were considered to have moderate levels of 
exudate.  Most ulcers were considered to have healthy and intact peri-ulcer skin in 
combination with a number of signs which may be important in ulcer healing.  On 
half of all patients experienced venous eczema, one half had induration and 
oedema.  Ankle brachial pressure index (ABPI) averaged 1.13, though this varied 
from 0.57 (indicating peripheral arterial disease) to 1.71.  In general, the ulcers 
were small in size with an average area as measured by planimetry of 7.6 cm2.  
There was a wide range of ulcer areas from 0.3 to 50.2 cm2. There was a 
difference in initial ulcer area between groups in favour of the control group but 
this did not achieve a standard level of significance.  Ulcer pain was present in 
60% of patients with relatively few patients experiencing severe pain (6%). The 
nature of the experienced pain was that it was largely intermittent in nature (85%). 
The average pain score on a 10 cm visual analogue scale was 3.3, which was 
similar between groups.  
 
Healing Outcomes. 
The primary outcome of this trial was time to complete healing over 12 weeks of 
follow up on an intention to treat (ITT) basis.  Per protocol analysis was also 
undertaken which gave similar results to the ITT and are not shown here. 
Table 4 gives the results of the ITT analysis up to 12 weeks.  It can be observed 
that a slightly higher proportion of patients’ ulcers healed in the control group 
compared with the Active group (49.1% versus 44.7%).  Most of the remaining 
ulcers remained unhealed at 12 weeks, though 8% were lost to follow up.  Of 
these, three were adverse events in the Active group, two of which were 
considered to be related to the dressings used. 
Figure 2 gives the Kaplan Meier Failure function.  This gives the estimated healing 
at weekly intervals over the 12 weeks.  The active group had slightly better healing 
over the duration of follow up as observed by the higher curve.  The hazard ratio 
for healing was 1.05.This difference did not approach a standard level of statistical 
difference (p=0.87).  After 4 weeks the estimated healing was 15.2% in the control 
group compared with 26.8% in the active group. After 12 weeks this had narrowed 
to 50.2% in the control group compared with 48.4% in the active group.  Analysis 
to 24 weeks saw little change with a hazard ratio of 1.14 with 95% confidence 
intervals of 0.70 to 1.84, p=0.60. 
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Further analysis was undertaken to observe the impact of confounding factors on 
the observed hazard ratio.  While most factors were not statistically associated 
with healing, two factors were identified as independent risk factors for healing. As 
expected larger ulcers were significantly less likely to achieve healing, whilst the 
presence of oedema made ulcer healing more likely.  This is rather counter-
intuitive and requires further investigation.  Adjustment for these factors increased 
the hazard ratio to 1.13 (95%CI 0.64, 2.02), though this still failed to achieve 
statistical significance (p=0.67).  
 
Quality of Life  
Table 5 gives the VLU-QOL scores for the three domains at the three time points, 
namely, baseline; 12 weeks and 24 weeks.  At baseline the scores were similar 
and at subsequent assessments the scores reduced indicating an improvement in 
quality of life.  The regression analysis showed that over the follow up there was 
little difference between the active and control group for any of the domains. While 
perceived pain as assessed by the VA scale reduced during follow up, there was 
no difference between groups. 
Cost and Cost effectiveness 
Table 6 gives the cost of products and nurse time over the follow up period to 
healing, withdrawal or to 12 weeks. The total number of dressing changes was 
472 in the 47 patients randomised to active group compared with 782 in the 
control group.  The total cost of care up to the point of healing or withdrawal were 
£27,853 (mean per patient £525) in the control group compared with £20,507 
(mean per patient £436) in the active group. As expected the costs of the primary 
dressings were higher in the active group compared with the control group at 
£4,692 versus £2,216, however this cost difference was more than offset by the 
reduction in nursing time associated with the fewer treatment visits.  
In addition to the primary dressings, other dressings were used as secondary 
dressings. The overall costs were similar between the randomised groups at £233 
versus £259 respectively. 
Bandages were used to provide compression in these patients.  There was a 
substantially higher cost of bandages in the control group compared with the 
active group at £3,864 versus £2,597.  Hosiery was not costed as these were not 
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renewed at each dressing change and were used with healed ulcers to prevent re-
ulceration. 
 
The cost per healed ulcer was in favour of the active group at £977 compared with 
£1071 in the control group. 
 
The Markov model results indicated that the total cost of care over the 12 weeks 
was £28,831 in the control group with a total of 187 ulcer free weeks.  For the 
active group the total cost was £23,801 with 175 ulcer free weeks. The 
incremental cost (control-active) was £5,031 and the Incremental healed weeks 
was 12.  The cost per additional week healed in the control group was £419.25. 
This indicates that whilst the control group had slightly better outcome in terms of 
ulcer free weeks, this came at a substantial extra cost of care implying that there 
was no advantage in terms of cost effectiveness between groups. 
 
Adverse Events. 
Overall there were 26 adverse events recorded in 18 patients.  Of these 8 events 
were recorded in patients in the control group compared with 18 in the active 
group.  In total 7 patients in the control group and 11 patients in the Active group 
were affected by at least one adverse event.  The majority of AEs were related to 
pain. Of these, only three were considered to be related to the dressing in the 
Active group versus none in the control group.  
 
Substudy examining Protease Activity 
 
Of the 100 patients randomised 98 had a baseline measure of protease activity. 
This semi-quantitative method gives a score from zero (no detectable protease 
activity) to 10 (maximum protease activity). For the purposes of this analysis a score 
of 5 or over was considered to be high protease activity which could benefit from the 
use of the test products.   
 
In total, 57/98 (58%) were considered to have high protease activity at baseline.  Of 
these, 29 were in the control group and 28 in the active group.  In the control group 
13/29 (44.8%) healed compared with 14/28 (50.0%) in the active group.  Figure 3 
gives the Kaplan Meier failure estimates for these patients with high initial protease 
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activity.  It shows that there was a clear separation between the two randomised 
groups with the active group having consistently higher healing over the 12 week 
period.  The hazard ratio in this analysis was 1.35, with wide 95% confidence 
intervals (0.63 to 2.87) p=0.44.  Clearly this is a small sample size, though it does 
indicate the potential for a larger trial to confirm this effect. 
 
The total cost of care on treatment in the control group was £14,979 compared with 
£11,939 in the active group, with 13 and 14 healed ulcers respectively.  The cost per 
healed ulcer was £1,152.23 in the control group compared with £852.79 in the active 
group a reduction of 26%.    
 
Using a similar Markov model as before this sub group had a total cost of care over 
12 weeks of £14,979 with 92 ulcer free weeks.  This compared with a cost of 
£12,528 and 121 ulcer free weeks in the active group.  The incremental cost 
difference was £2,450 between the control and active group.  The incremental 
weeks healed was -29 weeks.  From this it is shown that the active group 
experienced a higher number of ulcer free weeks but at a lower overall cost. This 
indicates that the active treatment dominates in this analysis, and therefore provides 
evidence that the active group was more cost effective than the control treatments. 
 
 
Discussion 
 
Evidence on the effectiveness of Oxyzyme and Iodozyme is largely limited to in vitro 
studies and case studies.  However, a recent review of the literature on Oxyzyme 
highlighted the evidence from a number of case series in the literature [12]. The 
Wound Healing Research Institute in Cardiff published a series of 31 patients with 
chronic venous ulcers [13].  After six weeks using Oxyzyme 32% had healed and 
58% had drastically improved.  In Toronto 20 patients with ulcers of various 
aetiologies were followed for four weeks [14].  A total of 18% healed, 68% improved, 
5% were static and 9% deteriorated. A larger pilot of 100 patients from 27 European 
countries with a variety of aetiologies found 10% healed, 63% improved, 16% static 
and 11% deteriorated after 6 weeks of treatment [15].  Because of the lack of 
comparative data the present trial was designed to provide information on the 
introduction of the two products into routine clinical practice by undertaking a 
randomised controlled trial compared with standard care.  This was a preliminary 
study with sample size set at one hundred patients in total. A formal sample size 
calculation was not undertaken as there was insufficient evidence on the potential 
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benefits of using these products on the measured outcomes.  It was anticipated that 
this study would provide such evidence.  While inferential statistics were carried out 
it was not anticipated that a standard level of statistical significance would be 
achieved in a comparison of randomised groups in either the primary or secondary 
outcomes that were defined. 
 
In general the protocol was adhered to, though there was evidence that the two 
active dressings were interchanged on a regular basis in the active group.  
Moreover, the trial was originally designed to examine the effects in both venous 
and mixed arterio-venous ulcers.  However of the 100 patients randomised only 
seven had an ankle brachial pressure index of less than 0.8 and so would qualify as 
a mixed arterio-venous ulcer.    This was despite 44 patients being considered as A-
V ulcers according to the nurse making the initial assessment. 
 
Those randomised to active treatment performed better in the early stages of 
treatment with 26.8% healing in the active group compared with 15.2% in the control 
group up to 4 weeks.  However as the study progressed, the graphs became closer 
indicating a similar healing rate beyond this early stage. This phenomenon is 
interesting and may benefit from further investigation. 
 
The secondary objectives were to determine the most cost effective method of 
managing these patients.  Whilst the cost of individual dressings in the active 
treatment group was substantially higher this was more than offset by the increased 
nursing and other costs caused by patients in the control group being seen more 
frequently.  The average costs were £526 per patient in the control arm compared 
with £436 in the active arm.  With the active arm costing less per healed ulcer at 
£976 versus £1071. The Incremental cost effectiveness ratio (ICER) indicated that 
while the control group had marginally better outcomes in terms of ulcer free weeks 
this was at a much higher cost.  This situation is common when introducing new 
treatments.  One might expect a better outcome, but at a higher cost.  The situation 
in this trial is rather unusual in that the test treatment was somewhat cheaper 
overall, but provided a slightly poorer outcome.  However, when only patients with 
high protease activity were analysed there was a clear difference in cost 
effectiveness both in terms of cost per healed ulcer, but also in terms of cost of ulcer 
free weeks in which the active group dominated. This indicates that the active group 
provided a better outcome at a lower cost.   While it has to be acknowledged that 
the high PA group was not strictly randomised in that they were a subset of the main 
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trial, this does provide compelling evidence of the potential for cost effectiveness 
using these new dressings. 
 
In terms of the patient related outcomes while there was good evidence of an 
improvement in health related quality of life in patients on treatment, there was little 
difference between the two randomised groups.  This is consistent with a number of 
trials that have been undertaken in relation to the healing of venous ulcers using 
different bandage and dressing combinations [16,17]. 
 
The British National Formulary (BNF) identifies seven wound care products in its 
section on protease modulating matrix dressings [10].  It does however give the 
caveat that “Protease-modulating matrix dressings alter the activity of proteolytic 
enzymes in chronic wounds; the clinical significance of this approach is yet to be 
demonstrated”.  Recent work has examined the potential for protease modifying 
products.  A small randomised trial (n=75) examined how the wound bed 
preparation was altered by the use of a protease modulating hydrogel in patients 
with venous ulcers [18].  After 14 days there was evidence of significant reduction in 
fibrin and necrotic tissue and increase in granulation tissue in the actively treated 
group compared with a control hydrogel.  Moreover, a study of compression therapy 
indicated that protease activity decreased following compression therapy, with 
reductions in certain MMPs associated with higher healing at 4 weeks [19].      
 
Evidence from randomised clinical trials has been limited in patients with venous 
ulceration.  In 2002 Vin et al published the results of a trial of 73 patients 
randomised to either collagen and oxidised regenerated cellulose (ORC) dressing 
(Promogran) or non-adherent dressing [20].  Their conclusion was that 20% more 
wounds healed or improved over the 12 week follow up which just failed to achieve a 
standard level of statistical significance (p=0.0797). In a smaller trial of 30 patients 
with follow up to two weeks using the same active therapy versus 10 patients using 
moist wound healing, the authors concluded that there was improved quality of 
healing and pain levels which occurred as early as one week after starting the 
therapy [21].  The only large trial of this nature was undertaken in diabetic patients 
comparing ORC with saline gauze as a control dressing [22]. This failed to 
demonstrate a significant difference between the randomised groups in the 271 
patients entered into this trial.   
 
Despite the lack of evidence from appropriate randomised controlled trials the 
present study gives some indication of how protease inhibitory dressings have the 
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potential for improving healing in patients with high initial protease activity.  Those 
patients in the active group have shifted their healing graph to the left (figure 2), 
indicating a quicker response to healing compared with the control group, though 
the study was not of sufficient size to demonstrate statistical significance.  Healing 
would appear to occur on average 1-2 weeks sooner than in the control group over 
the 12 week period.  At the end of 12 weeks the healing rates were 51% and 45% 
respectively.   
 
In conclusion, the results of the present study provide some useful information on 
the potential for the treatment of patients with high protease activity.  It also 
indicates that there is a good cost effectiveness argument in favour of using higher 
cost dressings if this provides a longer wear time, and less frequent visits for 
treatment.  Clearly, more evidence is needed to confirm these results.  
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Table 1.  Basic Demographic Information and Allied Health Problems 
 
 Control Active Total 
 N=53 N=47 N=100 
Age (years) 
Mean 69.4  69.7  69.5  
Standard deviation 13.5  13.2  13.3  
Minimum 31.3  39.3  31.3  
Maximum 91.4  92.5  92.5  
Count 53  46  99  
       
 N Percent N Percent N Percent 
Gender 
Male 29 54.7 23 48.9 52 52.0 
Female 24 45.3 24 51.1 48 48.0 
Total 53  47  100 100.0 
Diabetes 
Yes 8 15.1 6 12.8 14 14.0 
No 45 84.9 41 87.2 86 86.0 
Total 53  47  100 100.0 
Diabetes Type 
I 0 0 3 50.0 3 21.4 
II 8 100.0 3 50.0 11 78.6 
Method of control       
Insulin 2 25.0 3 50.0 5 35.7 
Non-insulin 6 75.0 3 50.0 9 64.3 
       
Rheumatoid Arthritis 
Yes 7 13.2 4 8.5 11 11.0 
No 46 86.8 43 91.5 89 89.0 
Total 53  47  100 10 
Smoker 
Yes 6 11.3 6 12.8 12 12.0 
No 47 88.7 41 87.2 88 88.0 
Total 53  47  100 100.0 
Hypertension 
Yes 25 47.2 17 36.2 42 42.0 
No 28 52.8 30 63.8 58 58.0 
Total 53  47  100 100.0 
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Table 2.  Factors Related to Venous and Cardiovascular Disease 
 Control Active Total 
 N Percent N Percent N Percent 
Varicose veins 
Yes 33 62.3 37 78.7 70 70.0 
No 20 37.7 10 21.3 30 30.0 
Total 53  47  100 100.0 
       
Varicose vein surgery 
Yes 13 24.5 17 36.2 30 30.0 
No 40 75.5 30 63.8 70 70.0 
Total 53  47  100 100.0 
       
History of Deep vein thrombosis 
Yes 6 11.3 7 14.9 13 13.0 
No 47 88.7 40 85.1 87 87.0 
Total 53  47  100 100.0 
       
History of pulmonary embolism 
Yes 2 3.8 0 0 2 2.0 
No 51 96.2 47 100.0 98 98.0 
Total  53  47  100 100.0 
       
History of myocardial infarction 
Yes 5 10.4 1 2.1 6 6.0 
No 48 89.6 46 97.9 94 94.0 
Total 53  47  100 100.0 
       
History of stroke 
Yes 2 3.8 3 6.4 5 5.0 
No 51 96.2 44 93.6 95 95.0 
Total 53  47  100 100.0 
       
History of Transient Ischaemic Attack (TIA) 
Yes 1 1.9 1 2.1 2 2.0 
No 52 98.1 46 97.8 98 98.0 
Total 53  47  100 100.0 
       
Arterial leg surgery 
Yes 3 5.7 1 2.1 4 4.0 
No 50 94.3 46 97.9 96 96.0 
Total 53  47  100 100.0 
       
Angioplasty 
Yes 1 1.9 0 0 1 1.0 
No 52 98.1 47 100.0 99 99.0 
Total 53  47  100 100.0 
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Table 3.  Ulcer Details 
 Control Active Total 
 N Percent N Percent N Percent 
Side 
Right 22 41.5 22 47.8 44 44.4 
Left 31 58.5 24 52.2 55 55.6 
 53  46  99  
Episodes 
First 19 35.8 17 36.2 36 36.0 
One previous  16 30.2 9 19.1 25 25.0 
2-5 episodes 11 20.8 14 29.8 25 25.0 
>5 episodes 7 13.2 7 14.9 14 14.0 
Total 53  47  100 100.0 
Ulcer present on contralateral limb 
Yes 5 9.4 8 17.0 13 13.0 
No 48 90.6 39 83.0 87 87.0 
Total 53  47  100 100.0 
Ulcer position on leg *  
Medial malleolus 22 41.5 17 36.2 39 39.0 
Lateral malleolus 10 18.9 10 21.3 20 20.0 
Tibial crest 11 20.8 8 17.0 19 19.0 
Calf 5 9.4 6 12.8 11 11.0 
Other 7 13.2 9 19.1 16 16.0 
Total 55  50  105  
Ulcer Duration (months) 
mean 20.0  17.6  18.9  
SD 56.5  40.3  49.5  
Ulcer aetiology 
Venous 30 56.6 26 55.3 56 56.0 
Mixed A-V 23 43.4 21 44.7 44 44.0 
Total 53  47  100 100.0 
Level of exudate 
None 13 25.0 13 28.2 26 26.5 
Low 23 44.2 24 52.2 47 48.0 
Moderate 16 30.8 9 19.6 25 25.5 
 52  46  98  
Peri-wound skin** 
Healthy & Intact 39 73.6 33 70.2 72 72.0 
Varicose eczema 26 49.1 25 53.2 51 51.0 
Hard Induration  25 47.2 29 61.7 54 54.0 
Oedema 26 49.1 22 46.8 48 48.0 
Maceration 9 17.0 5 10.6 14 14.0 
Other 2 3.8 1 2.1 3 3.0 
Ankle Brachial Pressure Index 
Mean 1.12  1.14  1.13  
SD 0.21  0.24  0.23  
 
Wound Area Measurement (cm2) 
Mean 7.1  8.1  7.6  
SD 10.0  10.2  10.1  
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Table 3 (continued) 
Ulcer pain  
Present 33 62.3 27 57.4 60 60.0 
Absent 20 37.7 20 42.6 40 40.0 
Total 53  47  100 100.0 
       
None 20 37.7 20 42.6 40 40.0 
Mild 11 20.8 10 21.3 21 21.0 
Moderate 18 34.0 15 31.9 33 33.0 
Severe 4 7.5 2 4.3 6 6.0 
Total 53  47  100 100.0 
       
Continuous 4 12.1 5 19.2 9 15.3 
Intermittent 29 87.9 21 80.8 50 84.7 
Total 33  26  59 100.0 
       
VA-pain       
Mean 3.4  3.3  3.3  
SD 3.5  3.4  3.5  
*ulcer position may have been on more than one location  
**patients may have had more than one description of the peri-ulcer skin 
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Table 4.  Intention to Treat Healing Outcomes and Reasons for Withdrawal up to 12 
weeks 
 Control Active Total 
 N Percent N Percent N Percent 
 
Healed 26 49.1 21 44.7 47 47.0 
Unhealed 25 47.2 20 42.6 45 45.0 
Lost to follow up 2 3.8 6 12.8 8 8.0 
Reason      100.0 
 142: Patient 
withdrew as 
preferred the Active 
dressings 
114:AE: Hospitalised 
chest pain 
 
176: Administrative: 
incomplete 
116: AE: Pain 
 121: Administrative: 
incomplete 
 137: Patient 
diagnosed with 
thyroid disease 
 150: Wound static  
?fungating 
carcinoma 
 225: AE: Pain & 
discomfort 
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Table 5.  Health Related Quality of Life at different time points  
 Control Active Difference 
(95%CI) 
p-value 
 n  n    
Activities   
Baseline 53 39.6 (26.8) 46 40.0 (25.3)   
12 weeks 49 31.3 (24.9) 38 28.8 (25.8) 0.04 (-10.2,10.3) 0.99 
24 weeks 45 25.3 (27.9) 39 23.1 (23.3)   
Psychological   
Baseline 51 41.5 (28.9) 46 46.7 (28.1)   
12 weeks 49 32.4 (27.2) 39 36.9 (26.7) 4.8 (-6.2,15.8) 0.40 
24 weeks 45 27.0 (27.4) 38 28.3 (28.1)   
Symptom distress   
Baseline 51 42.5 (24.4) 45 46.4(21.4)   
12 weeks 49 32.6 (22.4) 39 36.1 (25.4) 3.9 (-5.9,13.6) 0.44 
24 weeks 46 23.5 (26.2)  37 26.1 (27.7)   
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Table 6.  Costing Analysis for Dressings, Bandages and Nursing Time  
 Control Active Total 
N 53  47  100  
Visits for treatment 
Mean 14.8  10.04  12.54  
Total visits 782  472  1254  
       
Primary dressing costs (£) 
Mean 41.83  99.84  69.09  
Total Cost 2216.74  4692.32  6909.06  
       
Secondary dressing costs (£) 
Mean 4.90  4.96  4.93  
Total Cost 259.56  233.24  492.80  
       
Bandage Costs (£) 
Mean 72.91  55.26  64.61  
Total cost 3864.37  2597.09  6461.46  
       
Dressing Packs (£) 
Mean 7.52  5.12  63.95  
Total cost 398.82  240.72  639.54  
       
Staffing costs @ £27 per visit 
Mean 398.38  271.15  338.58  
Total Cost 21114.00  12744.00  33858.00  
       
Total cost of dressings, Bandages & Nursing time 
Mean 525.54  436.33  483.61  
Total cost 27853.49  20507.37  48360.86  
       
Number healed 26  21  47  
       
Cost per healed 
ulcer 
1071.29  976.54  1028.95  
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Figure 1.  Trial Flow Diagram
Randomised (n=100) 
Control (n=53) 
Received intervention (n=53)  
Did not receive intervention 
(0) 
Active (n=47) 
Received intervention (n=47)  
Did not receive intervention 
(0) 
Lost to follow up (n=0) 
Discontinued (n=6)  
Hospitalised (1) 
Administrative failure (1) 
Thyroid disease (1) 
?Carcinoma (1) 
Pain (2) 
 
Lost to follow up (n=0) 
Discontinued (n=2)  
Patient choice (1) 
administrative failure (1) 
Analysed (n=53) 
Excluded (n=0) 
Analysed (n=47) 
Excluded (n=0) 
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Figure 2.  Kaplan Meier Failure Estimates over 12 weeks given by 
Randomised Groups 
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Hazard Ratio =1.13, (95%CI 0.64 to 2.02), p=0.67.  
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Figure 3.  Kaplan Meier Failure Estimates over 12 weeks for Patients 
with high Protease Activity given by Randomised Groups 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 5 10 15
analysis time
rand = 0 rand = 1
Kaplan-Meier failure estimates
 
 
 
Hazard Ratio =1.35, (95%CI 0.63 to 2.87), p=0.44.  
 
 
 
 
 
 
